Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
TUG1
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
miR-34a/EZH2
Cancer name
Acute Myeloid Leukemia
Cancer site
Leukemia
Treatment type
Chemotherapy
Drug
Adriamycin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Down
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
TUG1 knockdown overcame ADR resistance of AML by epigenetically enhancing miR-34a expression, providing a novel therapeutic target for AML.
Tissue resource
samples of bone marrow from patients with acute myeloid leukemia
human bone marrow stromal cell lines HS-5
human acute myeloid leukemia cell lines HL60
Experiment
qRT-PCR,Luciferase reporter assay
Institute
the Shangqiu First People's Hospital
American Type Culture Collection
Country
China
USA
Continent
Asia
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.